# Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

> **NCT01039376** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 480 (actual)

## Conditions studied

- Leukaemia, Lymphocytic, Chronic

## Interventions

- **BIOLOGICAL:** Ofatumumab
- **OTHER:** Observation

## Key facts

- **NCT ID:** NCT01039376
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05-06
- **Primary completion:** 2017-02-20
- **Final completion:** 2018-06-26
- **Target enrollment:** 480 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2019-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01039376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01039376, "Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01039376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*